Welgene Biotech Co.,Ltd. (TPEX:6661)
Taiwan · Delayed Price · Currency is TWD 18.60
-0.50 (-2.62%)
At close: Feb 11, 2026
Welgene Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 1.64 | 1.11 | -2.65 | 9.55 | 13.7 | 29.77 |
Depreciation & Amortization | 27.51 | 28.72 | 27.06 | 18.86 | 19.02 | 18.15 |
Other Amortization | 0.02 | 0.08 | 0.19 | 0.19 | 0.19 | 0.29 |
Loss (Gain) From Sale of Assets | -0.18 | -0.37 | 0.11 | - | 0.02 | -0.33 |
Loss (Gain) From Sale of Investments | - | - | - | 4.19 | -5.04 | - |
Loss (Gain) on Equity Investments | - | - | - | - | 2.89 | -1.38 |
Stock-Based Compensation | - | - | - | - | 0 | - |
Provision & Write-off of Bad Debts | 0.18 | 0.15 | -0.6 | -1.41 | 0.19 | 0.9 |
Other Operating Activities | 3.96 | 4.49 | -9.62 | 3.46 | -5.33 | -3.64 |
Change in Accounts Receivable | -7.2 | 4.04 | -1.06 | 36.6 | -22.37 | 35.44 |
Change in Inventory | 2.83 | 12.76 | -10.64 | -8.85 | -7.99 | 9.51 |
Change in Accounts Payable | 11.5 | -0.47 | -1.88 | 6.46 | -2.92 | -4.73 |
Change in Unearned Revenue | 5.22 | 9.95 | -0.78 | -17.08 | 23.11 | -35.75 |
Change in Other Net Operating Assets | 1.23 | -4.38 | -0.49 | -0.54 | -4.22 | -6.45 |
Operating Cash Flow | 46.7 | 56.08 | -0.37 | 51.43 | 11.25 | 41.77 |
Operating Cash Flow Growth | 19.35% | - | - | 357.29% | -73.08% | -50.94% |
Capital Expenditures | -18.21 | -4.81 | -27.73 | -26.86 | -4.38 | -5.91 |
Sale of Property, Plant & Equipment | 0.48 | 0.55 | - | - | 0.24 | 0.54 |
Cash Acquisitions | - | - | -12.8 | - | - | - |
Sale (Purchase) of Intangibles | -0.7 | - | - | - | - | - |
Investment in Securities | -53.5 | -41.37 | 46.22 | -42.16 | -5.67 | -7.06 |
Other Investing Activities | -1.61 | 0.43 | 0.32 | 1.03 | -0.53 | 2.83 |
Investing Cash Flow | -73.54 | -45.19 | 6 | -67.99 | -10.34 | -9.6 |
Short-Term Debt Issued | - | - | - | - | 5.56 | - |
Long-Term Debt Issued | - | 2 | 45 | - | - | - |
Total Debt Issued | 59 | 2 | 45 | - | 5.56 | - |
Short-Term Debt Repaid | - | -2 | -0.21 | -1.35 | - | -4 |
Long-Term Debt Repaid | - | -24.86 | -18.38 | -11.97 | -11.35 | -11.35 |
Total Debt Repaid | -30.79 | -26.86 | -18.59 | -13.33 | -11.35 | -15.35 |
Net Debt Issued (Repaid) | 28.21 | -24.86 | 26.41 | -13.33 | -5.79 | -15.35 |
Issuance of Common Stock | - | - | - | - | 69.99 | - |
Common Dividends Paid | - | - | -4.23 | -11.29 | -25.68 | -27.77 |
Other Financing Activities | -2.95 | -0.66 | 1.72 | -0 | -0 | -0.01 |
Financing Cash Flow | 25.26 | -25.52 | 23.91 | -24.62 | 38.52 | -43.12 |
Net Cash Flow | -1.58 | -14.64 | 29.54 | -41.18 | 39.43 | -10.95 |
Free Cash Flow | 28.49 | 51.27 | -28.1 | 24.57 | 6.87 | 35.86 |
Free Cash Flow Growth | -9.84% | - | - | 257.63% | -80.84% | -53.25% |
Free Cash Flow Margin | 7.79% | 15.90% | -10.02% | 7.63% | 2.20% | 9.01% |
Free Cash Flow Per Share | 1.22 | 2.20 | -1.21 | 1.05 | 0.30 | 1.72 |
Cash Interest Paid | 3.01 | 2.66 | 1.86 | 0.19 | 0.17 | 0.23 |
Cash Income Tax Paid | - | 0.11 | 7.03 | 0.28 | 7.05 | 10.05 |
Levered Free Cash Flow | 24.52 | 46.79 | -17.18 | 25.9 | 2.14 | 30.3 |
Unlevered Free Cash Flow | 26.51 | 48.64 | -15.54 | 26.08 | 2.41 | 30.71 |
Change in Working Capital | 13.58 | 21.91 | -14.85 | 16.59 | -14.4 | -1.98 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.